THE 2015 ALZHEIMER'S DISEASE CONGRESS

AGENDA

23rd - 25th June 2015
London, UK
This three day event will discuss aspects of Alzheimer's Disease development and treatment in an informal academic setting. Topics for discussion include prediction and prevention strategies, vaccine development, drug discovery and care. With plenty of opportunity for networking and debate, this informal international meeting will bring you up to date with current research and thinking regarding Alzheimer's Disease.

This event has [CPD accreditation](http://www.regonline.co.uk/Alz2015)

[http://www.regonline.co.uk/Alz2015](http://www.regonline.co.uk/Alz2015)

Hashtag: #Alz2015
## Contents

**Agenda**

Day 1: Disease Initiation and Progression

- Introduction by the Chair
- Oral Inflammation, Tooth Loss, Risk Factors, and Association with Progression of Alzheimer’s Disease
- Eye-drops of G-CSF Gene Ameliorate Brain Function in Preclinical Neurological Disorder
- Oral Presentations
- Is Alzheimer’s disease (AD) infectious?
- Session Break
- Oral Presentations
- The emerging epidemic of dementia in Indigenous Australians
- Oral Presentations

Day 2: Therapeutics and Treatment

- Introduction by the Chair
- Mitochondrial and synaptic dysfunction in Alzheimer’s disease
- Oral Presentations
- Online information about the prevention of Alzheimer’s disease: The good, the bad, and the ugly
- Loss of Tau function impairs autophagic amyloid clearance: the potential of autophagy-inducing cancer drugs for AD treatment
- Oral Presentations
- 5-HT4 receptor agonists and multi-target directed ligands: novel promising agents for prevention of Alzheimer’s disease
- Oral Presentation
- Imaging Brain Injury in Diabetes
- Oral Presentation

Day 3 Session 1: Diagnosis, pathogenesis and prognosis

- Introduction by the Chair
- Aberrant cell cycle in Alzheimer’s disease lymphocytes: diagnostic prospects
- Oral Presentations
- Oral Presentation
- Clusterin: a garbage disposal system you can’t do without
- Oral Presentations
- Interspecies comparative gene expression profiling revealed impaired insulin production and insulin signaling in Alzheimer's disease brains: The Hisayama Study
- Treatment of Alzheimer with novel biologics

Day 3 Session 2: Management and Care

- Introduction by the Chair
- Oral Presentations
- Diagnosis of mild cognitive disorders in older adults: the usefulness of evaluation of Activities of Daily Living

**About the Speakers**

- Philip K. Liu
- Sim K. Singhrao

---

Day 1

5

Session Break

Oral Presentations

Is Alzheimer’s disease (AD) infectious?

Oral Presentations

The emerging epidemic of dementia in Indigenous Australians

Oral Presentations

Day 2: Therapeutics and Treatment

Introduction by the Chair

Mitochondrial and synaptic dysfunction in Alzheimer’s disease

Oral Presentations

Online information about the prevention of Alzheimer’s disease: The good, the bad, and the ugly

Loss of Tau function impairs autophagic amyloid clearance: the potential of autophagy-inducing cancer drugs for AD treatment

Oral Presentations

5-HT4 receptor agonists and multi-target directed ligands: novel promising agents for prevention of Alzheimer’s disease

Imaging Brain Injury in Diabetes

Oral Presentation

Day 3 Session 1: Diagnosis, pathogenesis and prognosis

Introduction by the Chair

Aberrant cell cycle in Alzheimer’s disease lymphocytes: diagnostic prospects

Oral Presentations

Oral Presentation

Clusterin: a garbage disposal system you can’t do without

Oral Presentations

Interspecies comparative gene expression profiling revealed impaired insulin production and insulin signaling in Alzheimer's disease brains: The Hisayama Study

Treatment of Alzheimer with novel biologics

Day 3 Session 2: Management and Care

Introduction by the Chair

Oral Presentations

Diagnosis of mild cognitive disorders in older adults: the usefulness of evaluation of Activities of Daily Living

**About the Speakers**

Philip K. Liu

Sim K. Singhrao
Is there WIFI?
I don't want my photograph on any Euroscicon promotional material
How can I keep up to date with Euroscicon Events?
I don’t want my photograph on any Euroscicon promotional material
Is there WIFI?
### Agenda (Talk times include 5 – 10 minutes for questions)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 09:00 – 10:00 | Exhibitions open

| 10:00 – 10:20 | Introduction by the Chair

| 10:20 – 10:45 | Oral Presentations

| 10:45 – 11:10 | Oral Presentations

| 11:10 – 11:40 | Oral Presentations

| 11:40 – 11:45 | Oral Presentations

| 11:55 – 12:10 | Oral Presentations

| 12:10 – 12:25 | Oral Presentations

| 12:25 – 12:50 | Oral Presentations

| 12:50 – 13:50 | Oral Presentations

| 13:50 – 14:15 | Oral Presentations

| 14:15 – 14:45 | Oral Presentations

| 14:45 – 15:15 | Oral Presentations

| 15:15 – 15:40 | Oral Presentations

| 15:40 – 16:05 | Oral Presentations

| 16:05 – 16:35 | Oral Presentations

| 16:35 – 17:00 | Oral Presentations

---

**Day 1: Disease Initiation and Progression**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 16:05 – 16:20 | *The special phospholipids plasmalogens, which have been reduced in the Alzheimer’s disease patients, facilitate hippocampal-dependent memory by maintaining BDNF signaling*

| 16:20 – 16:35 | *Is Alzheimer’s disease (AD) infectious?*

| 16:35 – 17:00 | Chairman’s Summing Up

---

**Registration and Refreshments**

**Dr. Giulio Maria Pasinetti**, Icahn School of Medicine at Mount Sinai, NY, USA

**Dr. Simon K. Sinohag**, Oral & Dental Sciences Research Group, School of Medicine & Dentistry, University of Central Lancashire, Preston, UK

**Dr Philip K. Liu**, Massachusetts General Hospital and Harvard Medical School, MA, USA

**Speakers’ photo, Refreshments, Poster viewing, Sponsors exhibition**

---

**Session Break**

**Lunch, Poster viewing, Sponsors exhibition**

**Registration and Refreshments**

**Refreshments, Last poster viewing, Last Sponsors exhibition**

**Last poster viewing, Last Sponsors exhibition**

**Refreshments, Last poster viewing, Last Sponsors exhibition**

**Last poster viewing, Last Sponsors exhibition**

**Last poster viewing, Last Sponsors exhibition**

**Close of Session**

---

**Is Alzheimer’s disease (AD) infectious?**

**Prof. Frank O. Bastian**, MD, LSU Agricultural center, Baton Rouge, LA & Professor of Pathology, Tulane Medical School, New Orleans, LA, US

**Alterations in the trafficking of the Amyloid Precursor Proteins result in endo-lysosomal defects and neuronal decline**

**Assoc. Prof. Carmela Matrone**, Ph.D., Dept. of Biomedicine, Aarhus University, Aarhus, Denmark

**Novel aptamer targeted neuron pro survival therapy in Alzheimer’s disease intervention**

**Joan Smith Sonneborn**, Ph.D Emeritus Professor Zoology & Physiology University of Wyoming, Laramie, Wyoming; 82072

**Behavioral and psychological disturbances in dementia**

**CA Hermoso**, C Pelegrín, FJ Olivera; Luis vives. Zaragoza, Zaragoza. Spain

**The emerging epidemic of dementia in Indigenous Australians**

**Assoc. Prof. Robert Parker**, Top End Mental Health Services, Northern Territory Australia

**Tau promotes synaptic dysfunction in AD**

**Prof. Alain Buisson**, Neuroscience, Universite Joseph Fourier Grenoble, La Tronche, France

---

**The Special Phospholipids Plasmalogens, which have been reduced in the Alzheimer’s disease patients, facilitate hippocampal-dependent memory by maintaining BDNF signaling**

**M. Shamim Hossain**, Ornit Chiba

**Md. Shamim Hossain**, Ornit Chiba

**Yuichi Abe**, Yuichi Abe

**Masanori Honsho**, Yukio Fujiki

**Kiyotaka Miake**, Hidetaka Fuchuu

**Toshihiko Katafuchi**, Toshihiko Katafuchi

**School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong, China.

---

**Is Alzheimer’s disease (AD) infectious?**

**Prof. Frank O. Bastian**, MD, LSU Agricultural center, Baton Rouge, LA & Professor of Pathology, Tulane Medical School, New Orleans, LA, US

**Alterations in the trafficking of the Amyloid Precursor Proteins result in endo-lysosomal defects and neuronal decline**

**Assoc. Prof. Carmela Matrone**, Ph.D., Dept. of Biomedicine, Aarhus University, Aarhus, Denmark

**Novel aptamer targeted neuron pro survival therapy in Alzheimer’s disease intervention**

**Joan Smith Sonneborn**, Ph.D Emeritus Professor Zoology & Physiology University of Wyoming, Laramie, Wyoming; 82072

**Behavioral and psychological disturbances in dementia**

**CA Hermoso**, C Pelegrín, FJ Olivera; Luis vives. Zaragoza, Zaragoza. Spain

**The emerging epidemic of dementia in Indigenous Australians**

**Assoc. Prof. Robert Parker**, Top End Mental Health Services, Northern Territory Australia

**Tau promotes synaptic dysfunction in AD**

**Prof. Alain Buisson**, Neuroscience, Universite Joseph Fourier Grenoble, La Tronche, France

---

**The Special Phospholipids Plasmalogens, which have been reduced in the Alzheimer’s disease patients, facilitate hippocampal-dependent memory by maintaining BDNF signaling**

**M. Shamim Hossain**, Ornit Chiba

**Md. Shamim Hossain**, Ornit Chiba

**Yuichi Abe**, Yuichi Abe

**Masanori Honsho**, Yukio Fujiki

**Kiyotaka Miake**, Hidetaka Fuchuu

**Toshihiko Katafuchi**, Toshihiko Katafuchi

**School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong, China.

---

**Is Alzheimer’s disease (AD) infectious?**

**Prof. Frank O. Bastian**, MD, LSU Agricultural center, Baton Rouge, LA & Professor of Pathology, Tulane Medical School, New Orleans, LA, US

**Alterations in the trafficking of the Amyloid Precursor Proteins result in endo-lysosomal defects and neuronal decline**

**Assoc. Prof. Carmela Matrone**, Ph.D., Dept. of Biomedicine, Aarhus University, Aarhus, Denmark

**Novel aptamer targeted neuron pro survival therapy in Alzheimer’s disease intervention**

**Joan Smith Sonneborn**, Ph.D Emeritus Professor Zoology & Physiology University of Wyoming, Laramie, Wyoming; 82072

**Behavioral and psychological disturbances in dementia**

**CA Hermoso**, C Pelegrín, FJ Olivera; Luis vives. Zaragoza, Zaragoza. Spain

**The emerging epidemic of dementia in Indigenous Australians**

**Assoc. Prof. Robert Parker**, Top End Mental Health Services, Northern Territory Australia

**Tau promotes synaptic dysfunction in AD**

**Prof. Alain Buisson**, Neuroscience, Universite Joseph Fourier Grenoble, La Tronche, France
Day 2: Therapeutics and Treatment

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45–09:30</td>
<td>Exhibitions open</td>
</tr>
<tr>
<td>09:30–10:05</td>
<td>Introduction by the Chair</td>
</tr>
<tr>
<td>10:05–10:25</td>
<td>Mitochondrial and synaptic dysfunction in Alzheimer’s disease</td>
</tr>
<tr>
<td>10:25–10:45</td>
<td>Development of allosteric activators of the Trk receptors for neuroprotection in AD</td>
</tr>
<tr>
<td>10:45–11:15</td>
<td>Oral Presentations</td>
</tr>
<tr>
<td>11:15–11:45</td>
<td>Session Break</td>
</tr>
<tr>
<td>11:45–12:05</td>
<td>Online information about the prevention of Alzheimer’s disease: The good, the bad, and the ugly</td>
</tr>
<tr>
<td>12:05–12:25</td>
<td>Loss of Tau function impairs autophagic amyloid clearance: the potential of autophagy-inducing cancer drugs for AD treatment</td>
</tr>
<tr>
<td>12:25–12:30</td>
<td>Session Break</td>
</tr>
<tr>
<td>12:15–12:40</td>
<td>RA HAS THE POTENTIAL EFFECT OF TREATING AD BY REGULATING PDE/CAMP/CRER PATHWAY</td>
</tr>
<tr>
<td>12:30–12:45</td>
<td>Memory groups for mild cognitive impairment: what is the benefit?</td>
</tr>
<tr>
<td>13:10–13:15</td>
<td>Session Break</td>
</tr>
<tr>
<td>13:15–13:40</td>
<td>Nanoliposomes for diagnosis and therapy of Alzheimer's - Recent Progress</td>
</tr>
<tr>
<td>14:00–14:55</td>
<td>Oral Presentation</td>
</tr>
<tr>
<td>14:55–15:05</td>
<td>APE1/REF-1 IN ASSOCIATION WITH GINKGOLIDE B AUGMENTS MITOCHONDRIAL OXPHOS AGAINST Aβ(25-35)-INDUCED OXIDATIVE STRESS</td>
</tr>
<tr>
<td>15:05–15:20</td>
<td>NICKE DEVELOP B-LYMPHOCYTE DEPENDENT DELAYED COGNITIVE DEFICITS WEEKS AFTER STROKE</td>
</tr>
<tr>
<td>15:20–15:50</td>
<td>Session Break</td>
</tr>
<tr>
<td>15:50–16:10</td>
<td>New Cellular and Animal Models for Drug Discovery in Alzheimer’s Disease</td>
</tr>
<tr>
<td>16:10–16:30</td>
<td>Imaging Brain Injury in Diabetes</td>
</tr>
<tr>
<td>16:30–17:00</td>
<td>Oral Presentation</td>
</tr>
<tr>
<td>17:00</td>
<td>Chairman’s Summing Up</td>
</tr>
<tr>
<td></td>
<td>Close of Session</td>
</tr>
</tbody>
</table>
Day 3 Session 1: Diagnosis, pathogenesis and prognosis

09:00 – 10:05 Exhibitions open

Registration and Refreshments

10:05 – 10:20 Introduction by the Chair

Professor Mark R Wilson, School of Biological Sciences, Faculty of Science, Medicine & Health, University of Wollongong, Wollongong, Australia

10:20 – 10:40 Aberrant cell cycle in Alzheimer’s disease lymphocytes: diagnostic prospects

Professor Urszula Wojtała, Head of the Laboratory of Advanced Preclinical Research Neurobiology Center, Nencki Institute of Experimental Biology, Warsaw, Poland

10:40 – 11:00 Oral Presentations

10:40 – 10:50 AUTOMATIC VERSUS EXECUTIVE SEMANTIC MEMORY IMPAIRMENT IN EARLY ALZHEIMER’S DISEASE: A POSSIBLE DIAGNOSTIC TOOL?

C. Carta & A. Venneri
University of Sheffield, Department of Neuroscience, Medical School, Sheffield, S10 2RX, UK

10:50 – 11:00 PROGRESSION PATTERN OF BRAIN MINERAL DEPOSITION AS A DIFFERENTIAL INDICATOR OF COGNITIVE DECLINE

L. Claudio, M.C. Valdés Hernández, A. Glatz, J.M. Wardlaw, J. Starr
1 College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK
2 Centre for Clinical Brain Sciences, Department of Neuroimaging Sciences, University of Edinburgh, Edinburgh, UK
3 Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, UK

11:00 – 11:30 Session Break

Speakers’ photo, Refreshments, Poster viewing, Sponsors exhibition

11:30 – 11:50 Oral Presentation

11:30 – 11:40 NEUROPSYCHIATRIC SYMPTOMS AND DEMENTIA IN PARKINSON’S DISEASE

Authors H. Alzahrani, A. Venneri
University of Sheffield, Royal Hallamshire Hospital, Sheffield S10 2JF

11:40 – 11:50 ARE SYMPTOMS OF DEPRESSION AND ANXIETY PREDICTIVE OF THE INCIDENCE OF ALZHEIMER’S DISEASE?

FINDINGS FROM THE AUSTRALIAN IMAGING, BIOMARKERS & LIFESTYLE (AIBL) STUDY OF AGING

R. Goodsell1, M. Albrecht1,2, R. Kane1 & L. Foster1,3
1 School of Psychology & Speech Pathology, Curtin University
2 Maryland Psychiatric Research Center, School of Medicine, University of Maryland
3 Neurosciences Unit, Health Department of WA

11:50 – 12:10 Clusterin: a garbage disposal system you can’t do without

Professor Mark R Wilson, School of Biological Sciences, Faculty of Science, Medicine & Health, University of Wollongong, Wollongong, Australia

12:10 – 12:30 Oral Presentations

12:10 – 12:20 RED BLOOD CELLS: A NEW PLAYER IN ALZHEIMER’S DISEASE PATHOGENESIS

Francesco Mistlì, Cristina Carelli-Alinovi2, Bruno Giardina2,3
1 Human, Social and Health Department, University of Cassino and Southern Lazio, V. S. Angelo, Loc. Folcara, 03043 Cassino (FR), Italy
2 Biochemistry and Clinical Biochemistry Institute, Catholic University, School of Medicine, L.go F. Vito n.1, 00168 Rome, Italy;
3 CNR- Istituto di Chimica del Riconoscimento Molecolare (ICRM), L.go F. Vito n.1, 00168 Rome, Italy;

12:20 – 12:30 BETA-AMYLOID Oligomerization is Associated with the Generation of a Typical Peptide Modification Fingerprint Which Can Be Specifically Targeted Using Novo-epitope Antibodies

A. Schmid, N. Rudinskiz, D. Demurtas, P. Ockl, M. Albrecht, R. Kane & L. Foster

12:30 – 12:50 Interspecies comparative gene expression profiling revealed impaired insulin production and insulin signaling in Alzheimer’s disease brains: The Hisayama Study

Dr Yusaku Nakaheppu, DVM, D.Sc. Distinguished Professor and Director of Research Center for Nudetoid Pool, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan

12:50 – 13:10 Treatment of Alzheimer with novel biologics

Dr Mourad Tayaibi, Surrey University, Guildford, Surrey, UK

13:10 – 14:10 Session Break

Lunch, Poster viewing Sponsors exhibition

Day 3 Session 2: Management and Care

14:10 – 14:40 Introduction by the Chair

Various phenotypes of Alzheimer’s disease and management strategies

Dr Chuang-Kuo Wu, M.D., Ph.D., FANA, Director, Alzheimer’s Disease Program, Texas Tech University Health Sciences Center, School of Medicine, Lubbock, Texas, USA

14:40 – 15:00 Reduction in Antipsychotic Medication Use Among US Nursing Home Residents: Regulation Revisions and a National Partnership

Professor Jane R. Mart, Pharm.D, Associate Dean for Academic Programs, Professor of Pharmacy Practice, College of Pharmacy, South Dakota State University, USA

15:00 – 15:20 Caregiver burden in dementia in rural Australia

Ms Kaye Ervin, Researcher and Lecturer Rural Health, University of Melbourne, Vic, Australia

15:20 – 15:50 Session Break

Refreshments, Last poster viewing, Last Sponsors exhibition

15:50 – 16:10 Oral Presentations

15:50 – 16:00 FUNCTIONAL MEMORY DISORDER - AN IMPORTANT DIFFERENTIAL DIAGNOSIS IN THE MEMORY CLINIC-K EY FEATURES AND REVIEW OF DIAGNOSTIC CRITERIA

Daniel Blackburn, Chris Elsey, Danielle Jones, Sarah Wakefield, Kirtsy Harkness, Annalena Venneri, Paul Drew, Markus Reuber

16:00 – 16:10 DESIGN OF MEMORY AIDS AGENT SERVICE BASED LOCATION AND TIME FOR PEOPLE WITH DEMENTIA

Seki TOYONO, Hironori Horuchi, Sachio SAIKAI, Shinriko MATSUMOTO, Naoko KISHIDA, Head of the Laboratory of Advanced Preclinical Research Neurobiology Center, Nencki Institute of Experimental Biology, Warsaw, Poland

16:10 – 16:30 Diagnosis of mild cognitive disorders in older adults: the usefulness of evaluation of Activities of Daily Living

Dr Patricia De Vriendt, Vrije Universiteite Brussel & University college Artevelde Ghent, Belgium

16:30 – 16:50 Driving quality care for people with dementia in nursing homes: The impact of large scale inter-professional student clinical placements.

Dr Andrew Robinson RN, MNS, PhD, Professor of Aged Care Nursing, School of Health Sciences, Wicking Dementia Research and Education Centre, University of Tasmania, Hobart, Tasmania, Australia

16:50 – 17:00 Chairman’s Summing Up

Close of Event
About the Speakers

Day 1

Sim K. Singhrao, Oral & Dental Sciences Research Group, School of Medicine & Dentistry, University of Central Lancashire, Preston, UK
Sim's interest in research in neurodegenerative diseases was nurtured by the influence of her mentor Dr Gillian Cole (Consultant Neuropathologist) and later by Dr James W. Neal (Consultant Neuropathologist). Sim obtained her M. Phil. degree at Cardiff University. Sim moved from the pathology Department to pursue her PhD in the Complement Biology Group at Cardiff University, headed by Professor B. Paul Morgan (Biochemistry and Immunology). This was a very interesting time for establishing the inflammatory hypothesis of Alzheimer's diseases. Following three postdoctoral research posts on aspects of non-CNS inflammatory diseases at Cardiff, Sim took up her current Senior Research Fellow position in the School of Medicine and Dentistry at the University of Central Lancashire, where she is pursuing research in periodontal disease and its association with Alzheimer's disease in support of the aetiological hypothesis.

Philip K. Liu, PhD, AA Martinos Center for Biomedical Imaging, Massachusetts General Hospital and the Harvard Medical School, Charlestown, MA, USA
Dr. Liu is a native of Taiwan; he has obtained BS degree (Chemistry, Westminster College, New Wilmington, PA), MS (Physiology) and Ph.D. (Genetics) degrees at Michigan State University; he received postdoctoral training (gene action of aging) at University of Washington Medical School (WA). He served as faculty member at Case Western Reserve University (OH), UT-MD Anderson Cancer Center and Baylor College of Medicine (Houston, TX). He is now an Associate Professor of Radiology at Massachusetts General Hospital and Harvard Medical School. He has published more than 50 peer-reviewed papers and submitted eight pending US patent applications.

Muralidhar Hegde, Assistant Professor, Houston Methodist Hospital Research Institute, Houston, Texas, United States
Dr. Hegde earned his Ph.D. in Biochemistry and Neurosciences from the University of Mysore, India in 2006. He performed his graduate research at the Max-Planck Institute of Biophysical Chemistry, Gottingen, Germany as a DST-DAAD visiting fellow, and at the Indian Institute of Science (IISc), Bangalore, India. He held a faculty (Assistant Professor) appointment at the University of Texas Medical Branch at Galveston, Texas, USA before becoming a member of the Houston Methodist Research Institute in 2013. As a member of the Research Institute cancer and neuroscience research programs, he directs a research program focusing on understanding the role of genome damage repair in cell death (neurodegenerative diseases) and cell proliferation (cancer) and its potential exploitation in therapeutics. Dr. Hegde has also been a member of grant review boards for the Alzheimer's Association, USA and the Motor Neuron Disease Association, UK. He is an Associate Editor for the Journal of Alzheimer’s Disease and serves on the editorial boards of the American Journal of Neurodegenerative Diseases and the Chinese Journal of Biology.

Frank O. Bastian, MD, Professor of Animal Science, LSU Agricultural center, Baton Rouge, LA & Professor of Pathology, Tulane Medical School, New Orleans, LA, US
Frank Bastian, MD, a Neuropathologist (Duke University Medical Center, 1972), has dedicated his career to identifying the causal transmissible agent of Creutzfeldt-Jakob disease (CJD), a fatal rapidly progressive neurodegenerative disease of humans. Currently Dr. Bastian is working on related transmissible spongiform encephalopathies (TSE) in sheep (scrapie) and deer (chronic wasting disease), which along with bovine spongiform encephalopathy (‘mad cow disease’) represent potential reservoir for CJD. Dr. Bastian has published extensively, including a monograph entitled 'Creutzfeldt-Jakob disease and other transmissible spongiform encephalopathies- Mosby/Year Book, 1991' used widely as a reference. REF ‘Case for Spiroplasma in Pathogenesis of TSE’ JNEN, 73:104, 2014.

Carmela Matrone, Ph.D., Dept. of Biomedicine, Aarhus University, Aarhus, Denmark
Carmela Matrone obtained her PhD in Neuroscience and became specialist in Pharmacology at the University of Naples, Faculty of Medicine (Italy). After that, she worked as Post Doc before, and Young Independent Researcher later, at the European Brain Research Institute in Rome, under the supervision of prof RL Montalcini, (NGF Nobel Prize) and prof Calissano P. In this period she manly focused her studies on the role of NGF in modulating APP signaling and activity in animal model of Alzheimer’s disease. She is currently working at Aarhus University as Associate Professor, further investigating the mechanism of regulation of APP metabolism and trafficking in the premature aging and dementia.
Robert Parker, Director of Psychiatry, Top End Mental Health Services, Northern Territory, Australia
Adjunct Associate Professor Parker is Director of Psychiatry with Top End Mental Health Services in the Northern Territory. He initially completed an Arts Degree in Anthropology and Prehistoric Archeology before working in the Tiwi Islands of the NT for 3 years as an art and craft advisor. A medical degree and specialist training in psychiatry followed.

Alain Buisson, Neuroscience, Université Joseph Fourier Grenoble, La Tronche, France
Professor of Neuroscience at the University J. Fourrier Grenoble 1
Group leader at Grenoble Institut Neurosciences working on "neurodegenerative diseases and synaptic dysfunction".

Day 2

Frank Gunn-Moore, BSc PhD FSB, professor, director of research, New medical and Biological Sciences Building, School of Biology, University of St Andrews, Scotland, UK
I am a molecular neurobiologist who studies the development and survival of mammalian neurons. My approach to achieve this has been one of combining all three science disciplines. My group has published >120 publications and we have made discoveries in understanding the early stages of Alzheimer's disease, where we have pioneered new models and identified potential therapeutic targets for the early stages of this disease. Using both molecular and novel biophysical techniques we have discovered novel signalling pathways that are involved in the growth and development of mammalian neurons. In addition, to overcome inherent problems with the manipulation of cells of the nervous system, we have developed novel technology that allows the controlled poration of cell impermeant biological material into any required cell type, and the controlled growth and sorting of cells by use of light.

Externally, I am Chair of the Biophotonics theme for Stanford and Scottish Universities partnership (SU2P); Chair of the Alzheimer's Research UK (ARUK) Scottish Network; Executive Committee for the Scottish Dementia Research Consortium which not only establishes links between scientists but acts a lobbying group against governments include the G8 summit of dementia; Executive Committee for the Scottish Universities Life Science Alliance (SULSA) which successfully helped in the obtaining €150M investment into the European Lead Factory (www.europeanleadfactory.eu), and the €30M Phentotypic Screening Centre (www.sulsa.ac.uk/research-facilities/uk-national-phenotypic-screening-centre), both of which are pan-European projects.

Nicholas Webster, Ph.D., M.A., Professor of Medicine, Chief, Division of Endocrinology and Metabolism, Associate Director for Shared Resources, Moores Cancer Center, University of California, San Diego, USA
After graduating from Cambridge University in 1981, Dr. Webster obtained a Ph.D. from Stanford University in California in 1986. He then moved to Strasbourg, France on a Royal Society Post-Doctoral Fellowship with Prof. Pierre Chambon. Dr. Webster joined the faculty of the Division of Endocrinology and Metabolism at UCSD in 1989, with a joint appointment at the VA San Diego Healthcare System starting in 1993. Dr. Webster is currently Chief of the Division of Endocrinology and Metabolism at UCSD and is Associate Director for Shared Resources at the Moores Cancer Center. Dr. Webster has an ongoing collaboration with Dr. Stan Krajewski at the Sanford-Burnham Medical Research Institute and Prof. Michael Pirrung of the University of California, Riverside to develop small-molecule, neuroprotective compounds that target the Trk family of receptors.

Ta Yuan Chang, PhD, Professor, Department of Biochemistry, Geisel School of Medicine at Dartmouth, Hanover, NH, USA
Dr. Chang's laboratory developed mutant CHO cells lacking cholesterol esterification, used these cells to clone the acyl-CoA:cholesterol acyltransferase 1 (ACAT1) gene, and demonstrated its role in medical physiology. His laboratory also isolated three other cholesterol mutants that enabled the discovery of three more genes (S2p, Scap, and Npc1) in cholesterol metabolism.

David Allsop, Professor of Neuroscience, Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, United Kingdom
David Allsop is Professor of Neuroscience at Lancaster University, UK. He has been working on Alzheimer's disease and other protein misfolding disorders for around 30 years, and has published more than 120 scientific papers. He was the first person to isolate amyloid plaques from human brain. He is a member of the Research Executive Committee of The Alzheimer’s Society, UK.
Julie Robillard, University of British Columbia, Djavad Mowafaghian Centre for Brain Health, Vancouver, BC, Canada
Dr. Robillard is Assistant Professor of Neurology at The University of British Columbia in Vancouver, Canada and faculty at the National Core for Neuroethics and at the Djavad Mowafaghian Centre for Brain Health. She leads a research program at the intersection of aging, ethics and new media and has developed innovative techniques for the analysis of brain health and social media. Dr. Robillard's research has been featured widely in broad-reaching media outlets such as the Wall Street Journal and the National Post, as well as in high impact publications and at international conferences.

Mourad Tayebi, Surrey University, Guildford, Surrey, UK
Mourad's research focuses on refining the therapeutic strategies through developing novel antibodies that would specifically recognize the oligomeric forms of misfolded proteins, including Aβ-peptide and tau. His team developed a panel of anti-PrP camelid antibodies able to transmigrate across the blood-brain barrier and enter the cell membrane of neurons (Jones et al, 2010; David et al. 2014). Mourad's team is interested in investigating the molecular mechanisms of protein aggregation. His team set out to demonstrate that aggregation of proteins is essentially needed to control and moderate protein function(s) and interaction(s) during physiological and pathological disturbances.

Sylvie Claeyse, PhD, HDR, Institut de Génomique Fonctionnelle, Université de Montpellier, Montpellier, France
Dr Sylvie is a permanent researcher at INSERM and the holder of an accreditation to supervise PhD students. During her PhD, she identified numerous splice variants of the 5-HT4 receptor, described for the first time the constitutive activity of this GPCR and engineered the first Gs-coupled RASSL. Then, she developed programs in molecular pharmacology on 5-HT4 receptor and initiated innovative research strategies, based on a deep knowledge, accumulated during the past years on signalling pathways engaged by this receptor. Her aim is now to propose new therapeutic agents that activate the non-amyloidogenic protective pathway for AD prevention.

Sophia G. Antimisiaris, University of Patras, Greece
S.G. Antimisiaris received her B.Pharm. (1984) and Ph.D in Pharmaceutics (1988) from Athens University, Greece. She worked as post-doc in School of Pharmacy, USC, L.A.-USA [1989 -1990] and Visiting Prof, School of Pharmacy, London [1992-1993]. From 2009 she is full Professor of Pharmacy, in Patras University, Greece, and Laboratory head as well as member of the FORTH/ICES Institute [from 2006]. SGAs research interests are in the area of controlled and/or targeted nanosized drug delivery system or nanomedicine development. She has received funding from National and European (FP6 & FP7) sources and Industry

Jordan L. Holtzman, University of Minnesota, USA
Professor Holtzman is a well known clinician and biochemist/cell biologist who has 160 peer reviewed original publications, reviews, and book chapters, including two invited reviews on Alzheimer's disease. Initially, his laboratory focused on the formation of toxic metabolites which covalently bind to the endoplasmic reticulum (ER). He found that a toxic metabolite of paracetamol bound to ER chaperones. This led him to investigate the cell biology of the ER, protein, processing pathway. In collaboration with Alzheimer's investigators, he began his studies on the role of ER decline in Alzheimer's leading to a new paradigm for the etiology of this condition. 

Myria Petrou, MA MBChB MS, Department of Radiology, Division of Neuroradiology, University of Michigan, Michigan, USA
Dr. Petrou received her undergraduate and medical degrees from the University of Cambridge in the UK. She then went on to complete her radiology training at the University of Michigan and her neuroradiology training at both the University of Michigan and Johns Hopkins. Dr. Petrou is currently an assistant professor at the University of Michigan, where she runs a laboratory focused on imaging of neurodegenerative diseases. Dr. Petrou also holds an MS degree in clinical research design from the University of Michigan School of Public Health.
Urszula Wojda, Head of the Laboratory of Advanced Preclinical Research Neurobiology Center, Nencki Institute of Experimental Biology, Warsaw, Poland

Urszula Wojda, PhD, Full Professor, Head of Laboratory of Advanced Preclinical Studies, Neurobiology Center, Nencki Institute in Warsaw. Her research focuses on verification in cellular and animal models of new potential diagnostic and therapeutic strategies for cancer and neurodegenerative disorders such as Alzheimer’s disease. Her expertise includes aberrant cell cycle regulation in AD neurons and patients’ peripheral cells. She conducted preclinical research at the Pasteur Institute, France, and at the National Institutes of Health, USA, and successfully collaborates with many scientific institutes worldwide. Since 2013 She serves as an expert for combating neurodegenerative diseases for the Polish Ministry of Science.

Selected recent publications:


Mark R Wilson, School of Biological Sciences, Faculty of Science, Medicine & Health, University of Wollongong, Wollongong, Australia

Prof Wilson has pioneered the field of extracellular proteostasis and has discovered a family of extracellular (secreted) chaperones that play key roles in this context. He has authored more than 90 publications, which includes 37 experimental papers and 7 reviews specifically addressing the structure and function of what is currently the most prominent extracellular chaperone, clusterin. He was also the first to show that in response to stress, clusterin can exit the secretory pathway and enter the cytosol where it can play a role in disposing of misfolded proteins.

Yusaku Nakabeppu, DVM, D.Sc. Distinguished Professor and Director of Research Center for Nucleotide Pool, Division of Neurofunctional Genomics, Department of Immunobiology and Neuroscience, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan

Yusaku Nakabeppu is a Professor at the Division of Neurofunctional Genomics, Department of Immunobiology and Neuroscience, Medical Institute of Bioregulation, Kyushu University, Japan. He is now serving as the Director of Research Center for Nucleotide Pool, Kyushu University. Dr. Nakabeppu graduated from Graduate School of Sciences, Kyushu University, with a Doctor of Science degree in 1984. He has performed postdoctoral work at Johns Hopkins University School of Medicine from 1987 to 1990. In 1997, he was appointed as a Professor at the Medical Institute of Bioregulation, Kyushu University, and elected as a Distinguished Professor at Kyushu University in 2010.

Chuang-Kuo Wu, M.D., Ph.D., FANA, Director, Alzheimer’s Disease Program, Texas Tech University Health Sciences Center, School of Medicine, Lubbock, Texas, USA

Dr Chuang-Kuo Wu is currently an endowed professor, specialized in Alzheimer’s disease and associated dementia disorders. He is a member of the steering committee of Taxes Alzheimer Research Consortium. Over the years, he has worked at Alzheimer's disease's centers of Northwestern University, Brown University and U.C. San Diego. He has published original research papers in the aging models and Alzheimer’s disease.
Jane R. Mort, Pharm.D., Associate Dean for Academic Programs, Professor of Pharmacy Practice, College of Pharmacy, South Dakota State University, USA

Jane R. Mort, PharmD is Professor of Pharmacy Practice and serves as Associate Dean for Academic Programs in the College of Pharmacy at South Dakota State University. During her 28 year career at South Dakota State University she has practiced pharmacy as a consultant to nursing homes, served as a member of a hospital based geriatric assessment team, and provided consultant services to the South Dakota quality improvement organization. She has been a fellow in the American Society of Consultant Pharmacists for over 20 years. Her scholarly work is focused on medication use in geropsychiatry.

Kaye Ervin, Researcher and Lecturer Rural Health, University of Melbourne, Vic, Australia

Kaye has been a nurse for thirty years, having held various roles in aged care. She has researched dementia in rural settings for the past 6 years with the University of Melbourne.

Patricia De Vriendt, Vrije Universiteit Brussel & University college Artevelde Ghent, Belgium

Patricia De Vriendt, (occupational therapist and Gerontologist (PhD)) is professor at the Vrije Universiteit Brussel (where she is studying frailty and cognitive disorders) and holds a position as head of the research group Care Innovation at the Artevelde University College (where she promotes research on Active Ageing). She focusses on (1) the usefulness of the evaluation of activities of daily living for diagnosis of mild cognitive decline in an older population and (2) the importance of having meaningful activities at older age. For her work on early detection of dementia she received several scientific prizes.

Andrew Robinson RN, MNS, PhD, Professor of Aged Care Nursing, School Of Health Sciences, School Of Aged Care Nursing, School Of Health Sciences, Wicking Dementia Research and Education Centre, University of Tasmania, Hobart, Tasmania, Australia

Andrew Robinson is Professor of Aged Care Nursing, in the School Of Health Sciences and Co-Director, Wicking Dementia Research and Education Centre (WDREC), University of Tasmania. As Co-Director of WDREC, Andrew oversees projects that span translational health services research, clinical and biomedical research, and education and workforce capacity, to tackle the leading issues related to the increasing numbers of people with dementia.

Discussion Sessions

The discussion sessions are an opportunity for informal questions and answers. This is an ideal opportunity to get advice and opinion from experts in this area. This session is not for questions about specific talks, which can be asked after the speakers session, but for discussing either general topics or specific issues.

There are three ways you can ask questions:

1. Before the session you can submit your question to Euroscicon staff at the registration desk,
2. Before and during the session you can submit a question or comments, by email, which will be provided on the day of the event
3. During the session you can put your hand up and join in

Session breaks

All breaks and registrations will take place in the exhibition area where there will be lunch and refreshments.

Please try to visit all the exhibition stands during this event. Not only do our sponsors enable Euroscicon to keep the registration fees competitive, but they are also here specifically to talk to you.
Lunch
All the chicken in our lunch buffet is Halal
We have a number of dishes that are gluten free
We have a range of vegetarian dishes which are separated from the meat and fish dishes

Frequently asked questions about our events

Is the delegate list available?
Yes this is available to everyone who attends the event and our sponsors.
It is available in real time. To access the list please just log into your registration details or use the QR code on right of the agenda card which is provided on the day of the event.
You will not be included in this list if you have opted out and you can do this by logging into your registration details. This list will not be sold or ever give out to third parties.

Can I have the speakers slides?
We cannot give out the slides from our speaker's presentations as they are deleted immediately after each event. If you require a particular set of slides please approach the speaker. We will however have a meeting report and you will be emailed when this report is published.

Can I have a notepad?
Notepads and pens are provided in the delegate bags and at the registration desk

How can I keep up to date with Euroscicon Events?
To keep updated on our events and other Life Science News, please sign up for our newsletter at www.eurosciconnews.com

I don’t want my photograph on any Euroscicon promotional material
Please let our tech person know

Is there WIFI?
Yes, please ask registration for log in details

Can I have a CPD certificate?
CPD certificates will be available in the exhibition hall after lunch

Please remember that EuroSciCon is a small independent company with no subsidies from society memberships or academic rates for venues. We try to be as reasonably priced as possible and our delegate rates are substantially lower than comparable commercial meeting organisations